These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
178 related articles for article (PubMed ID: 29611187)
1. Tandem haematopoietic stem cell transplantation for High Risk relapsed/refractory Hodgkin Lymphoma: a LYSA study. Deau B; Amorim S; Perrot A; Quittet P; Cornillon J; Chaoui D; Marolleau JP; Oberic L; Le Du K; Fornecker LM; Tournilhac O; Veillard AS; Chaillol I; Robin M; Tamburini J; Brice P Br J Haematol; 2018 May; 181(3):341-349. PubMed ID: 29611187 [TBL] [Abstract][Full Text] [Related]
2. Brentuximab vedotin as salvage treatment in Hodgkin lymphoma naïve transplant patients or failing ASCT: the real life experience of Rete Ematologica Pugliese (REP). Pavone V; Mele A; Carlino D; Specchia G; Gaudio F; Perrone T; Mazza P; Palazzo G; Guarini A; Loseto G; Eleonora P; Cascavilla N; Scalzulli P; Melpignano A; Quintana G; Di Renzo N; Tarantini G; Capalbo S Ann Hematol; 2018 Oct; 97(10):1817-1824. PubMed ID: 30054707 [TBL] [Abstract][Full Text] [Related]
3. Use of brentuximab vedotin as salvage therapy pre-allogeneic stem cell transplantation in relapsed/refractory CD30 positive lympho-proliferative disorders: a single centre experience. Mediwake H; Morris K; Curley C; Butler J; Kennedy G Intern Med J; 2017 May; 47(5):574-578. PubMed ID: 28247950 [TBL] [Abstract][Full Text] [Related]
4. Brentuximab vedotin prior to allogeneic stem cell transplantation in Hodgkin lymphoma: a report from the EBMT Lymphoma Working Party. Bazarbachi A; Boumendil A; Finel H; Mohty M; Castagna L; Peggs KS; Blaise D; Afanasyev B; Diez-Martin JL; Sierra J; Bloor A; Martinez C; Robinson S; Malladi R; El-Cheikh J; Corradini P; Montoto S; Dreger P; Sureda A Br J Haematol; 2018 Apr; 181(1):86-96. PubMed ID: 29468647 [TBL] [Abstract][Full Text] [Related]
5. Outcomes of patients with relapsed/refractory Hodgkin lymphoma progressing after autologous stem cell transplant in the current era of novel therapeutics: A retrospective analysis. Bair SM; Strelec L; Nagle SJ; Nasta SD; Landsburg DJ; Mato AR; Loren AW; Schuster SJ; Stadtmauer EA; Svoboda J Am J Hematol; 2017 Sep; 92(9):879-884. PubMed ID: 28512788 [TBL] [Abstract][Full Text] [Related]
6. Brentuximab Vedotin in Transplant-Naïve Relapsed/Refractory Hodgkin Lymphoma: Experience in 30 Patients. Zinzani PL; Pellegrini C; Cantonetti M; Re A; Pinto A; Pavone V; Rigacci L; Celli M; Broccoli A; Argnani L; Pulsoni A Oncologist; 2015 Dec; 20(12):1413-6. PubMed ID: 26500229 [TBL] [Abstract][Full Text] [Related]
7. Survival analysis of patients with Hodgkin lymphoma who failed high dose chemotherapy and autologous stem cell transplant. Elshenawy MA; Shahzad Rauf M; Elhassan TAM; Maghfoor I; Akhtar S Ann Hematol; 2018 Jul; 97(7):1229-1240. PubMed ID: 29484455 [TBL] [Abstract][Full Text] [Related]
8. Prospective study of brentuximab vedotin in relapsed/refractory Hodgkin lymphoma patients who are not suitable for stem cell transplant or multi-agent chemotherapy. Walewski J; Hellmann A; Siritanaratkul N; Ozsan GH; Ozcan M; Chuncharunee S; Goh AS; Jurczak W; Koren J; Paszkiewicz-Kozik E; Wang B; Singh S; Huebner D; Engert A; von Tresckow B Br J Haematol; 2018 Nov; 183(3):400-410. PubMed ID: 30168134 [TBL] [Abstract][Full Text] [Related]
9. Brentuximab vedotin followed by allogeneic transplantation as salvage regimen in patients with relapsed and/or refractory Hodgkin's lymphoma. Garciaz S; Coso D; Peyrade F; Fürst S; Duran S; Chetaille B; Brenot-Rossi I; Devillier R; Granata A; Blaise D; Bouabdallah R Hematol Oncol; 2014 Dec; 32(4):187-91. PubMed ID: 24301099 [TBL] [Abstract][Full Text] [Related]
10. Brentuximab vedotin compared with other therapies in relapsed/refractory Hodgkin lymphoma post autologous stem cell transplant: median overall survival meta-analysis. Bonthapally V; Yang H; Ayyagari R; Tan RD; Cai S; Wu E; Gautam A; Chi A; Huebner D Curr Med Res Opin; 2015; 31(7):1377-89. PubMed ID: 25950500 [TBL] [Abstract][Full Text] [Related]
11. Results of a Multicenter Phase II Trial of Brentuximab Vedotin as Second-Line Therapy before Autologous Transplantation in Relapsed/Refractory Hodgkin Lymphoma. Chen R; Palmer JM; Martin P; Tsai N; Kim Y; Chen BT; Popplewell L; Siddiqi T; Thomas SH; Mott M; Sahebi F; Armenian S; Leonard J; Nademanee A; Forman SJ Biol Blood Marrow Transplant; 2015 Dec; 21(12):2136-2140. PubMed ID: 26211987 [TBL] [Abstract][Full Text] [Related]
12. Reduced-intensity conditioning (RIC) and allogeneic stem cell transplantation (allo-SCT) for relapsed/refractory Hodgkin lymphoma (HL) in the brentuximab vedotin era: favorable overall and progression-free survival (OS/PFS) with low transplant-related mortality (TRM). Clin Adv Hematol Oncol; 2014 Feb; 12(2 Suppl 6):15-7. PubMed ID: 24870877 [No Abstract] [Full Text] [Related]
13. A targeted salvage therapy with Brentuximab vedotin in heavily treated refractory or relapsed pediatric Hodgkin lymphoma patients before and after stem cell transplantation. Taçyıldız N; Tanyıldız HG; Ünal E; Dinçaslan H; Asarcıklı F; Aksoy BA; Vatansever G; Yavuz G Turk J Pediatr; 2019; 61(5):671-676. PubMed ID: 32104998 [TBL] [Abstract][Full Text] [Related]
14. Brentuximab vedotin plus bendamustine: a highly active first salvage regimen for relapsed or refractory Hodgkin lymphoma. LaCasce AS; Bociek RG; Sawas A; Caimi P; Agura E; Matous J; Ansell SM; Crosswell HE; Islas-Ohlmayer M; Behler C; Cheung E; Forero-Torres A; Vose J; O'Connor OA; Josephson N; Wang Y; Advani R Blood; 2018 Jul; 132(1):40-48. PubMed ID: 29703778 [TBL] [Abstract][Full Text] [Related]
15. Brentuximab vedotin in patients with relapsed or refractory Hodgkin lymphoma who are Ineligible for autologous stem cell transplant: A Germany and United Kingdom retrospective study. Bröckelmann PJ; Zagadailov EA; Corman SL; Chirikov V; Johnson C; Macahilig C; Seal B; Dalal MR; Illidge T Eur J Haematol; 2017 Dec; 99(6):553-558. PubMed ID: 28949403 [TBL] [Abstract][Full Text] [Related]
16. The European Medicines Agency Review of Brentuximab Vedotin (Adcetris) for the Treatment of Adult Patients With Relapsed or Refractory CD30+ Hodgkin Lymphoma or Systemic Anaplastic Large Cell Lymphoma: Summary of the Scientific Assessment of the Committee for Medicinal Products for Human Use. Gravanis I; Tzogani K; van Hennik P; de Graeff P; Schmitt P; Mueller-Berghaus J; Salmonson T; Gisselbrecht C; Laane E; Bergmann L; Pignatti F Oncologist; 2016 Jan; 21(1):102-9. PubMed ID: 26621039 [TBL] [Abstract][Full Text] [Related]
17. Tandem versus single haematopoietic stem cell transplant and BV maintenance in relapsed/refractory Hodgkin lymphoma: A matched cohort analysis from the LYSA. Marouf A; Molinari N; Sibon D; Cottereau AS; Kanoun S; Antoine C; Debureaux PE; Cavalieri D; Fornecker LM; Casasnovas RO; Herbaux C; Amorim S; Rossi C; Bouscary D; Brice P; Ghesquieres H; Tamburini J; Deau B Br J Haematol; 2023 Jul; 202(2):379-383. PubMed ID: 37192755 [TBL] [Abstract][Full Text] [Related]
18. Single or tandem autologous stem-cell transplantation for first-relapsed or refractory Hodgkin lymphoma: 10-year follow-up of the prospective H96 trial by the LYSA/SFGM-TC study group. Sibon D; Morschhauser F; Resche-Rigon M; Ghez D; Dupuis J; Marçais A; Deau-Fischer B; Bouabdallah R; Sebban C; Salles G; Brice P Haematologica; 2016 Apr; 101(4):474-81. PubMed ID: 26721893 [TBL] [Abstract][Full Text] [Related]
19. Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin's lymphoma at risk of relapse or progression (AETHERA): a randomised, double-blind, placebo-controlled, phase 3 trial. Moskowitz CH; Nademanee A; Masszi T; Agura E; Holowiecki J; Abidi MH; Chen AI; Stiff P; Gianni AM; Carella A; Osmanov D; Bachanova V; Sweetenham J; Sureda A; Huebner D; Sievers EL; Chi A; Larsen EK; Hunder NN; Walewski J; Lancet; 2015 May; 385(9980):1853-62. PubMed ID: 25796459 [TBL] [Abstract][Full Text] [Related]
20. Brentuximab vedotin in relapsed/refractory Hodgkin lymphoma post-autologous transplant: meta-analysis versus historical data. Bonthapally V; Wu E; Macalalad A; Yang H; Shonukan O; Liu Y; Chi A; Huebner D Curr Med Res Opin; 2015 May; 31(5):993-1001. PubMed ID: 25772232 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]